

1 **Biallelic pathogenic variants in TRMT1 disrupt tRNA modification and induce a**
2 **syndromic neurodevelopmental disorder**

3
4 Stephanie Efthymiou^{1,#}, Cailyn P Leo^{2,#}, Chenghong Deng^{2,#}, Kejia Zhang², Sheng-Jia Lin³, Reza
5 Maroofian¹, Rauan Kaiyrzhanov¹, Renee Lin¹, Irem Karagoz¹, Annarita Scardamaglia¹, Daniel
6 Owrang^{4,5}, Valentina Turchetti¹, Friederike Jahnke^{4,5}, Cassidy Petree³, Anna V Derrick⁶, Mark I
7 Rees^{6,7}, Javeria Raza Alvi⁸, Tipu Sultan⁸, Chumei Li⁹, Marie-Line Jacquemont¹⁰, Frederic Tran-
8 Mau-Them^{11,12}, Maria Valenzuela-Palafoll¹³, Rich Sidlow¹⁴, Grace Yoon¹⁵, Michelle Morrow¹⁶,
9 Alexis Carere¹⁷, Mary O'Connor¹⁸, Julie Fleischer¹⁷, Erica H Gerkes¹⁸, Chanika Phornphutkul¹⁹,
10 Bertrand Isidor^{20,21}, Clotilde Rivier-Ringenbach²², Christophe Philippe^{11,23}, Semra H Kurul^{24,25,26},
11 Didem Soydemir²⁴, Bulent Kara²⁷, Deniz Sunnetci-Akkoyunlu²⁸, Viktoria Bothe²⁹, Konrad
12 Platzer²⁹, Dagmar Wieczorek³⁰, Margarete Koch-Hogrebe³¹, Nils Rahner³², Ann-Charlotte
13 Thuresson³³, Hans Matsson³³, Carina Frykholm³³, Sevcan Tuğ Bozdoğan^{34,35}, Atıl Bişgin^{34,35},
14 Nicolas Chatron^{36,37}, Gaetan Lesca^{36,37}, Sara Cabet^{38,39}, Zeynep Tümer^{40,41}, Tina D Hjortshøj⁴⁰,
15 Gitte Rønde⁴², Thorsten Marquardt⁴³, Janine Reunert⁴³, Erum Afzal⁴⁴, Mina Zamani^{45,46}, Reza
16 Azizimalamiri⁴⁷, Hamid Galehdari⁴⁵, Pardis Nourbakhshd⁴⁸, Niloofar Chamanrou^{45,46}, Seo-
17 Kyung Chung^{6, 49,50}, Mohnish Suri⁵¹, Paul J Benke⁵², Maha S Zaki⁵³, Joseph G Gleeson⁵⁴, Daniel
18 G Calame^{55,56,57}, Davut Pehlivan⁵⁷, Halil I Yilmaz⁵⁸, Alper Gezdirici⁵⁸, Aboufazl Rad⁵⁹, Iman
19 Sabri Abumansour^{60,61,62}, Gabriela Oprea⁵⁹, Jai Sidpra⁴⁶, Kshitij Mankad⁶³, Barbara Vona^{4,5},
20 Andrew E Fry^{64,65}, Gaurav K Varshney³, Henry Houlden^{1*}, Dragony Fu^{2*}

21 #These authors are equal first authors

22 * Correspondence: h.houlden@ucl.ac.uk (clinical studies and human genetics)

23 * Correspondence: dragonyfu@rochester.edu (functional /molecular studies)

24 **Affiliations**

- 25 1. Department of Neuromuscular disorders, UCL Queen Square Institute of Neurology,
26 London, WC1N 3BG, UK.
- 27 2. Department of Biology, Center for RNA Biology, University of Rochester, Rochester, New
28 York, USA.
- 29 3. Genes & Human Disease Research Program, Oklahoma Medical Research Foundation,
30 Oklahoma City, OK, 73104, USA.
- 31 4. Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen,
32 Robert-Koch-Str. 40, 37075, Göttingen, Germany.
- 33 5. Institute of Human Genetics, University Medical Center Göttingen, Heinrich-Düker-Weg 12,
34 37073, Göttingen, Germany.
- 35 6. Neurology Research Group, Institute of Life Science, Swansea University Medical School,
36 Swansea University SA2 8PP, UK.
- 37 7. Faculty of Medicine & Health, Camperdown, University of Sydney, Sydney, Australia.
- 38 8. Department of Pediatric Neurology, Institute of Child Health, Children's Hospital, Lahore
39 54590, Pakistan.
- 40 9. McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.
- 41 10. Unité de Génétique Médicale et Centre de Référence Anomalies du Développement et
42 Syndromes Malformatifs, CHU de la Réunion, Saint-Pierre, France.
- 43 11. Unité Fonctionnelle Innovation en Diagnostic Génomique des maladies rares, CHU Dijon
44 Bourgogne, Dijon, France.
- 45 12. INSERM UMR1231 GAD, F-21000, Dijon, France.
- 46 13. Department of Clinical and Molecular Genetics, Vall d'Hebron University Hospital and
47 Medicine Genetics Group, Vall d'Hebron Research Institute, Barcelona, Spain.
- 48 14. Department of Medical Genetics and Metabolism, Valley Children's Hospital, Madera,
49 California, USA.
- 50 15. Hospital for Sick Children, Toronto, Canada; University of Toronto, Toronto, Canada.
- 51 16. GeneDx, Gaithersburg MD USA.
- 52 17. Department of Pediatrics, Southern Illinois University School of Medicine, Springfield,
53 Illinois, USA.
- 54 18. Department of medical genetics, University of Groningen, University Medical Center
55 Groningen, Department of Genetics, The Netherlands.
- 56 19. Division of Human Genetics, Department of Pediatrics, Warren Alpert Medical School of
57 Brown University, Hasbro children's Hospital, RI, USA.
- 58 20. Centre Hospitalier Universitaire de Nantes, Service de Génétique Médicale, Nantes, France.
- 59 21. INSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
- 60 22. Hôpital Nord-Ouest, Service de Neuropédiatrie, Villefranche sur Saône, France.
- 61 23. Laboratoire de Génétique, Hôpital Mercy, CHR Metz-Thionville, Metz, France.
- 62 24. Department of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir,
63 Turkey.
- 64 25. Izmir Biomedicine and Genome Center, Dokuz Eylül University Health Campus, İzmir,
65 Turkey.
- 66 26. Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, İzmir,
67 Turkey.
- 68 27. Division of Pediatric Neurology, Department of Pediatrics, Kocaeli University, Kocaeli,
69 Turkey.

- 70 28. Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
71 29. Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
72 30. Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-
73 Heine-University Düsseldorf, Düsseldorf, Germany.
74 31. Vestische Kinder- und Jugendklinik Datteln, Abteilung für Neuropädiatrie, Datteln,
75 Germany.
76 32. MVZ Institute for Clinical Genetics and Tumor Genetics, Bonn, Germany.
77 33. Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala,
78 Uppsala University, 751 85, Uppsala, Sweden.
79 34. Cukurova University AGENTEM (Adana Genetic Diseases Diagnosis and Treatment
80 Center), Adana, Turkey.
81 35. Department of Medical Genetics, Cukurova University Faculty of Medicine, Adana, Turkey.
82 36. Hospices Civils de Lyon, Service de Génétique, Centre Labélisé Anomalies du
83 Développement CLAD Sud-Est, Lyon, France.
84 37. Institut Neuromyogène, Laboratoire Physiopathologie et Génétique du Neurone et du
85 Muscle, Equipe Métabolisme énergétique et développement neuronal, CNRS UMR 5310,
86 INSERM U1217, Université Lyon 1, Lyon, France.
87 38. Pediatric, Woman and Fetal Imaging Department, Hôpital Femme-Mère-Enfant, Hospices
88 Civils de Lyon, 69500 Bron, France.
89 38.
90 39. Institut NeuroMyoGène, CNRS UMR5292, INSERM U1028, Claude Bernard Lyon 1
91 University, 69000 Lyon, France.
92 40. Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital-
93 Rigshospitalet, Copenhagen, Denmark.
94 41. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of
95 Copenhagen, Copenhagen, Denmark.
96 42. Department of Paediatrics and Adolescent Medicine, University Hospital Herlev, Herlev,
97 Denmark.
98 43. Department of Paediatrics, Metabolic Diseases, University of Münster, Albert-Schweitzer-
99 Campus 1, 48149 Münster, Germany.
100 44. Department of Paediatric Neurology, Children's Hospital and Institute of Child Health,
101 Multan, Punjab 60000, Pakistan.
102 45. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz,
103 Iran.
104 46. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran.
105 47. Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center,
106 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
107 48. Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical
108 Sciences, Ahvaz, Iran.
109 49. Brain & Mind Centre, Faculty of Medicine & Health, Camperdown, University of Sydney,
110 Sydney, Australia.
111 50. Kids Research, Children's Hospital at Westmead, Sydney, Australia.
112 51. Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, City
113 Hospital Campus, Nottingham, NG5 1PB, UK.
114 52. Developmental Biology and Cancer Section, University College London Great Ormond
115 Street Institute of Child Health, London, UK, WC1N 1EH.

- 116 53. Clinical Genetics Department, Human Genetics and Genome Research Division, Centre of
117 Excellence of Human Genetics, National Research Centre, Cairo, Egypt.
- 118 54. Department of Neuroscience, Rady Children's Institute for Genomic Medicine, University of
119 California, San Diego, San Diego, California, USA.
- 120 55. Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics,
121 Baylor College of Medicine, Houston, TX, USA.
- 122 56. Texas Children's Hospital, Houston, TX, USA.
- 123 57. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX,
124 USA.
- 125 58. Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, Istanbul,
126 Turkey.
- 127 59. Arcensus GmbH, Rostock, Germany.
- 128 60. Neurogenetic section, Department of Pediatrics, King Faisal Specialist Hospital and Research
129 Center, Jeddah, Saudi Arabia.
- 130 61. Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah,
131 Saudi Arabia.
- 132 62. Department of Pediatric, International Medical Center, Jeddah, Saudi Arabia.
- 133 63. Department of Radiology, Great Ormond Street Hospital for Children, London, UK.
- 134 64. Institute of Medical Genetics, University Hospital of Wales, Cardiff, CF14 4XW, UK.
- 135 65. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14
136 4XW, UK.
- 137

138 **Abstract**

139 The post-transcriptional modification of tRNAs plays a key role in tRNA folding and function to
140 ensure proper levels of protein synthesis during growth and development. Pathogenic variants in
141 tRNA modification enzymes have been implicated in diverse human neurodevelopmental and
142 neurological disorders. However, the molecular basis for many of these disorders remains
143 unknown, thereby limiting our understanding and potential treatment of pathologies linked to
144 tRNA modification. Here, we describe an extensive cohort of 31 individuals from 24 unrelated
145 families with bi-allelic variants in the *tRNA methyltransferase 1 (TRMT1)* gene who present with
146 a syndromic neurodevelopmental disorder universally characterized by intellectual disability in
147 affected patients. Developmental delay, behavioral abnormalities and facial dysmorphisms
148 represent additional core phenotypes of this syndrome. The variants include novel and ultra-rare
149 *TRMT1* variants that segregate with clinical pathology. We found that a subset of variants causes
150 mis-splicing and loss of TRMT1 protein expression. Notably, patient cells with *TRMT1* variants
151 exhibit a deficiency in tRNA modifications catalyzed by TRMT1. Molecular analysis of *TRMT1*
152 variants reveal distinct regions of the TRMT1 protein required for tRNA modification activity
153 and binding, including a TRMT1 subdomain critical for tRNA interaction. Importantly, depletion
154 of TRMT1 in zebrafish is sufficient to induce developmental and behavioral phenotypes that
155 recapitulate those observed in human patients with pathogenic *TRMT1* variants. Altogether, these
156 findings demonstrate that loss of TRMT1-catalyzed tRNA modifications leads to a syndromic
157 form of intellectual disability and elucidate the molecular underpinnings of tRNA modification
158 deficiency caused by pathogenic TRMT1 variants.

159

160 **Keywords:** TRMT1; dimethylguanosine; intellectual disability; tRNA modification

161

162 **Introduction**

163 Intellectual disability (ID) is a neurodevelopmental disorder characterized by significant
164 limitations in intellectual ability and adaptive function with a prevalence estimated between 2%
165 and 3% in the general population (1). Genomic sequencing studies have identified an increasing
166 number of causative monogenic variants for ID in genes encoding a diverse group of proteins.
167 Notably, pathogenic variants in genes encoding RNA modification enzymes have been identified
168 as a cause of cognitive disorders in the human population (2-4). These findings highlight the
169 emerging role of tRNA modification in normal neurological development and function.

170 Human tRNA methyltransferase 1 (TRMT1) is a tRNA modification enzyme that
171 catalyzes the formation of *N*², *N*²-dimethylguanosine (m²,2G) in cytosolic and mitochondrial
172 tRNAs (5, 6). TRMT1 has been demonstrated to be responsible for nearly all m²,2G
173 modifications in the tRNA of human cells (6, 7). The m²,2G modification has been proposed to
174 play a role in tRNA structure and function (8-10). Human cells deficient in TRMT1 exhibit
175 decreased global protein synthesis and reduced cellular proliferation (6). TRMT1 has also been
176 found to be a cleavage target of the SARS-CoV-2 main protease, suggesting that perturbation of
177 tRNA modification patterns contributes to the cellular pathology of SARS-CoV-2 infection (11,
178 12). Intriguingly, neuronal activation induces a change in the subcellular distribution of TRMT1,
179 suggesting a role for TRMT1-catalyzed tRNA modification in neuronal transmission and
180 plasticity (7).

181 Frameshift variants in *TRMT1* have been identified as the cause for certain cases of
182 autosomal-recessive ID through exome sequencing (MRT68, MIM# 618302) (13-16). This was
183 followed by the identification of a single bi-allelic missense variant in *TRMT1* associated with

184 developmental delay, ID, and epilepsy (17). These studies suggest that TRMT1 plays a key role
185 in normal neurodevelopment and cognitive function. However, the impact of *TRMT1* variants on
186 protein expression and function remains unknown for most cases. Moreover, the sparse number
187 of *TRMT1* variants that have been identified and characterized has limited our understanding of
188 cognitive disorders associated with TRMT1 and their physiological consequences.

189 Here, we describe 31 affected individuals from 24 unrelated families presenting with
190 clinical features of ID in which exome or genome sequencing identified novel and ultra-rare bi-
191 allelic segregating *TRMT1* variants. To functionally characterize the bi-allelic *TRMT1* variants,
192 we explored tRNA modifications in proband-derived fibroblasts or lymphoblasts and quantified
193 m²,2G modifications in cellular tRNAs. Moreover, we investigated the effects of TRMT1-
194 associated ID (TRMT1-ID) variants on reconstitution of activity and interaction between
195 TRMT1 and tRNAs. These studies elucidate the molecular underpinnings of *TRMT1*-derived
196 disorders and significantly expand the spectrum of disease-causing TRMT1 variants.

197

198 **Results**

199 **Identification of pathogenic variants in *TRMT1* linked to neurodevelopmental disorders**

200 Using the GeneMatcher platform and data sharing with collaborators, we identified 24
201 unique families containing 31 individuals affected with neurodevelopmental disorders secondary
202 to bi-allelic variants in *TRMT1* (Figure 1A and 1B, Table 1, Supplementary Table 1). Pedigrees
203 in Figure 1 and Supplementary Table 1 are available upon request from the corresponding
204 authors. We identified 11 missense, 2 nonsense, 13 splice site and 8 frameshift variants. The
205 missense variants were classified as damaging by SIFT, PolyPhen-2, REVEL and Mutation
206 Taster, with a mean CADD score of 27. None of the variants identified were present in the

207 homozygous state in gnomAD v.3.1.2. Nine of the twenty-four identified *TRMT1* variants were
208 absent across multiple genetic databases (~1 million alleles), whereas the remaining variants
209 appear to be ultra-rare (Supplementary Table 1, available upon request from the corresponding
210 authors).

211 All detected variants were located within the conserved *S*-adenosylmethionine-dependent
212 methyltransferase domain (Figure 1C). Of the missense variants, p.Arg169Pro, p.Asp231Asn and
213 p.Arg323Cys are conserved from yeast to humans, while p.Gln332Arg, p.Cys348Arg and
214 p.Ser467Leu are semi-conserved (Figure 1D). p.Tyr445Leufs*28 was found in two independent
215 individuals (F12:S1 and F15:S1). Similarly, p.Gln219Hisfs*22 was found in two independent
216 families. Overall, these recurring variants suggest a possible founder effect.

217 Among the 31 affected individuals, 14 patients were identified with homozygous variants in
218 *TRMT1* and 14 patients contained compound heterozygous variants in *TRMT1*. Nineteen of the
219 individuals were male (61%) and 12 were female (39%). Consanguinity was reported in 13 families
220 (54%). Additionally, 11 of the families had a positive family history for neurological diseases
221 (48%). The median age at last follow-up was 11 years. The ethnic composition of the cohort is
222 diverse, including families of Pakistani, Caucasian, Middle Eastern, European, and Hispanic origin
223 (Table 1).

224

225 **Patients with bi-allelic *TRMT1* variants present with a core set of phenotypic features**

226 The 31 affected individuals with biallelic *TRMT1* variants exhibited a core set of
227 phenotypic features encompassing intellectual disability, global developmental delay, and facial
228 dysmorphism (Figure 2A, summarized in Table 1). Video recordings are available for affected

229 individuals from Family 1 (Supplementary Video 1 and 2). Detailed clinical history, case reports,
230 and videos are available upon request from the corresponding authors.

231 Intellectual disability (ID) or developmental delay (DD) for individuals of less than 5
232 years of age was reported in all patients who were tested (27/27). DD/ID varied in severity
233 among individuals and assessed as mild to moderate DD/ID in 17 out of 22 individuals, moderate
234 to severe DD/ID in 4 out of 22, and severe to profound DD/ID in 1 out of 22. Speech and
235 language development was delayed among all participants tested (29/29), with the median age
236 for first words spoken recorded at 40.5 months (range: 17 months to 8 years).

237 Motor milestones were delayed in the majority of tested cases (24/27), with median ages
238 of 9 months for unsupported sitting and 23 months for independent walking. Other gross motor
239 manifestations included an unsteady/broad-based gait (n=2), clumsiness (n=7), poor
240 coordination, and ataxia (n=6). Seizures were found in 58% of the patients (18/31), with a
241 median onset age of 16.5 months (range: 1 month to 27 months). Seizure semiology varied and
242 included febrile seizures (n=8), focal fits (n=3), and generalized tonic-clonic seizures (n=7). 35%
243 (n=9/24) of the conducted EEGs were reported as abnormal for these patients. Nine of 28 study
244 subjects had microcephaly with one person having developed secondary microcephaly with time
245 (F19). Additionally, two individuals showed macrocephaly.

246 Facial photographs and/or videos were reviewed for 13 patients from 10 families (Figure
247 2B, Supplementary Table 2, feature frequencies tabulated in Supplementary Table 3, data
248 available upon request from the corresponding authors). Based on this assessment, the most
249 frequently seen facial dysmorphic features of *TRMT1*-related neurodevelopmental delay include
250 high anterior hairline (46%), narrow forehead/bifrontal/bitemporal narrowing (54%), sparse
251 eyebrows or laterally sparse eyebrows (62%), up-slanting palpebral fissures (46%), wide/broad

252 nasal bridge (54%) and full or broad nasal tip (85%). The facial features found are relatively
253 non-specific and recognizable facial gestalt for this disorder was not appreciated.

254 Neurological assessments revealed hypotonia in 5 out of 27 individuals (19%), with 2
255 individuals presenting it as the primary complaint, while hypertonia was observed in 2
256 individuals. Other neurological features observed in the cohort included poor coordination/
257 ataxia (6/28) and intention tremor (3/28). Abnormal movements were reported in 9 out of 30
258 patients, with motor or verbal tics being the most common manifestation (6/9). A diverse range
259 of behavioral issues were reported in 20 out of 28 individuals, ranging from diagnosed ASD and
260 ADHD to parent-reported concerns such as hyperactivity, aggression, anxious behavior,
261 restlessness, poor autonomy, and irritability.

262 Feeding difficulties affected 41% of the patients (14 out of 29). Sleep apnea was present
263 in 2 patients, with one utilizing CPAP. Additionally, four individuals had hearing impairment.

264 Brain MRI was available for 12 individuals (Figure 2C, summarized in Supplementary
265 Figure 1). The most prevalent neuroimaging findings in our cohort were cerebral atrophy (7/12;
266 58%); cerebellar atrophy (6/12; 50%), which was either global (n=2), limited to the vermis
267 (n=2), or limited to the cerebellar hemispheres (n=2); and posterior thinning of the corpus
268 callosum (5/12; 42%). Two individuals (Family 5 and Family 20 Proband 1) exhibited global
269 brain atrophy. Altogether, these findings identify a core syndromic pattern associated with
270 biallelic TRMT1 variants that can co-occur with a diversity of dysmorphic, neurological, and
271 behavioural phenotypes.

272

273 **TRMT1 splice site variants alter splicing patterns**

274 A subset of *TRMT1* variants are predicted to alter mRNA splicing patterns based upon *in*
275 *silico* splice site prediction algorithms (Supplementary Table 4). To test the effects of the TRMT1
276 variants on splicing, we generated mini-gene splicing reporter plasmids cloned from the genomic
277 DNA of a healthy wildtype (WT) donor or affected patients. The splicing reporters were
278 transfected into 293T human embryonic cells and splicing analyzed by RT-PCR, sequencing, and
279 fragment analysis (Supplementary Figure 2, Supplementary Data 1, Supplementary Table 5 and
280 Supplementary Table 6).

281 The c.255-1G>T and c.310+5G>C variants are predicted to abolish the splice acceptor and
282 donor sites of exon 3, respectively, while the c.311-1G>A variant is predicted to abolish the splice
283 acceptor site of exon 4. The c.454-1G>C variant is predicted to eliminate the splice acceptor site
284 of exon 5. The c.255-1G>T, c.310+5G>C, c.311-1G>A, and c.454-1G>C variants were tested
285 using a construct containing introns 2 to 5. RT-PCR spanning exons 3 through 5 from cells
286 transfected with the WT construct showed a complex splicing pattern due to alternative splicing
287 that was analyzed through Sanger sequencing and fragment analysis (Figure 3A, Supplementary
288 Data 1). From fragment analysis, a total of 53% of protein coding transcripts in WT include exons
289 3 to 5 that were completely eliminated in assays for the c.255-1G>T, c.310+5G>C, and c.454-
290 1G>C variants with an abundance of only 10.6% in sample c.311-1G>A (r.255_641del,
291 p.Cys86Glnfs*24) (Supplementary Table 5 and Supplementary Table 6).

292 The c.1107-1G>A variant was predicted to abolish the splice acceptor site of exon 10 and
293 create a cryptic splice site 1 nucleotide downstream from the native canonical splice site that likely
294 causes a deletion of 1 bp and a frameshift r.1108del p.(Ala370Profs*11). The c.1107-1G>A variant
295 was evaluated using a construct spanning introns 8 to 10. RT-PCR of both WT and the c.1107-

296 1G>A variant showed two bands which we attribute to the pSPL3 vector (Figure 3B, gel). The
297 frameshift was validated by Sanger sequencing (Figure 3B, chromatograms).

298 The splice prediction scores for the c.1194G>A variant suggested either a cryptic donor
299 gain 14 bp from the native splice acceptor site or no splice effect. The c.1194G>A variant was
300 assayed using a construct spanning intron 10 to exon 12. The RT-PCR for the c.1194G>A variant
301 showed skipping of exon 11 and 12 leading to a frameshift (r.1177_1397del, p.Leu393Valfs*7)
302 that was validated with Sanger sequencing (Figure 3C). Altogether, our splicing analyses reveal
303 that a subset of *TRMT1* variants can induce aberrant splicing that are expected to reduce mRNA
304 abundance and/or produce altered protein products.

305

306 ***TRMT1* variants differentially impact TRMT1 protein levels**

307 To examine the impact of ID-associated *TRMT1* variants, we next investigated TRMT1
308 protein expression in available patient cell lines using immunoblotting. For the Asp231Asn
309 (D231N) missense variant in Family 14, we obtained fibroblast cells from the heterozygous
310 father (Patient 14f) and the homozygous offspring that were compared to a control fibroblast cell
311 line (control 1, WT fibroblast). The heterozygous D231N fibroblasts exhibited a ~2-fold increase
312 in TRMT1 protein compared to WT fibroblast cells (Figure 4A, compare lanes 1 and 2;
313 quantified in Figure 4B). The homozygous D231N fibroblast cell line exhibited an even greater
314 ~5-fold increase in TRMT1 protein levels compared to WT fibroblast cells (Figure 4A, compare
315 lanes 1 and 3; quantified in Figure 4B). These results suggest that the D231N variant affects the
316 folding of TRMT1 leading to increased stability of TRMT1 against degradation and/or turnover.

317 We also generated fibroblast cell lines from patients in families 1, 4, and 8 that harbor
318 *TRMT1* splicing variants (Table 2). We detected nearly complete loss of TRMT1 protein

319 expression in cell lines derived from two different members of Family 1 that have a homozygous
320 splicing variant that eliminates the splice acceptor site of exon 5 (Figure 4A, patients 1.1 and 1.2,
321 lanes 4 and 5; quantified in Figure 4C). Family 8 is compound heterozygous for a splice site and
322 a frameshift variant *in trans*. TRMT1 levels are also reduced to nearly undetectable levels in
323 fibroblasts from Family 8 (Figure 4A, Patient 8, lane 7; quantified in Figure 4C). The fibroblasts
324 from Patient 4 are compound heterozygous for the Gln332Arg (Q332R) missense variant and a
325 splice variant that is predicted to abolish the splice acceptor of exon 3 (c255-1G>T). We did not
326 detect a significant change in TRMT1 protein levels in the fibroblasts from Patient 4 compared
327 to controls (Figure 4C patient 4, lane 6, quantified in 4C).

328 For individuals from families 16 and 19, we derived lymphoblastoid cell lines (LCLs)
329 that were compared to control LCLs obtained from a healthy donor (control 2, WT-LCL). We
330 detected a substantial reduction in TRMT1 protein in the patient cell line from Family 16
331 containing a homozygous splicing variant predicted to abolish the splice acceptor site of exon 4
332 (Figure 4D, quantified in 4E). The patient from Family 19 harbors compound heterozygous
333 missense variants *in trans* in *TRMT1*. We detected no substantial change in TRMT1 protein
334 levels in the patient 19 LCL compared to control LCLs (Figure 4D, quantified in Figure 4E).
335 These results suggest that the Arg323Cys (R323C) and Ser467Leu (S467L) missense variants do
336 not significantly affect TRMT1 protein levels. Altogether, these results demonstrate that *TRMT1*
337 splice variants as well as certain missense variants can impact TRMT1 protein accumulation.

338

339 **TRMT1-ID patient cells exhibit a reduction in m²,2G modification in tRNAs**

340 We next tested the functional impact of *TRMT1* variants on tRNA modification in patient
341 cell lines. TRMT1 has been shown to generate the m²,2G modification at position 26 in human

342 tRNAs (6, 7). To monitor the m²,2G modification, we used a primer extension assay in which
343 the presence of m²,2G leads to a block of reverse transcriptase (RT). A decrease in m²,2G
344 modification allows for read-through and extension up to a subsequent RT-blocking
345 modification. We performed the primer extension assay on tRNA-Met-CAU and mitochondria
346 (mt)-tRNA-Ile-GAU, both of which contain m²,2G at position 26 (6, 17).

347 As reference, we performed the primer extension assay with RNA extracted from 293T
348 human embryonic cells. In the absence of RT, only background bands were detected in reactions
349 containing the radiolabeled probe and RNA from 293T human cells (representative gel shown in
350 Figure 5A and B, lane 1). Addition of RT led to the appearance of an extension product up to the
351 m²,2G modification at the expected position in both tRNA-Met-CAU and mt-tRNA-Ile-GAU in
352 293T human embryonic cells and a control fibroblast cell line from a healthy control with
353 wildtype *TRMT1* alleles (Figure 5A and B, lanes 2 and 3, 293T and WT control). Patient
354 fibroblast cells from Family 14 that are heterozygous for the D231N variant exhibit similar levels
355 of m²,2G modification in tRNA-Met-CAU and mt-tRNA-Ile-GAU compared to the control
356 fibroblast cell line (Figure 5A and B, compare lanes 3 and 4, quantified in Figure 5C and D). In
357 contrast, patient fibroblast cells from Family 14 that are homozygous for the D231N variant
358 exhibited nearly complete loss of the m²,2G modification block in tRNA-Met-CAU and mt-
359 tRNA-Ile-GAU (Figure 5A and B, compare lane 5 to lanes 3 and 4; quantified in Figure 5C and
360 D). These results indicate that the D231N variant impairs the methyltransferase activity of
361 TRMT1 to form m²,2G.

362 The m²,2G modification in tRNA-Met-CAU and mt-tRNA-Ile-GAU was also reduced in
363 patient-derived cell lines from families 1, 8, 16, 19, and 21 (Figure 5A and B, Supplementary
364 Figure 3, quantified in Figure 5C through F.). The cell lines from families 1 and 16 are

365 homozygous for *TRMT1* splicing variants, while the cell line from Family 8 is compound
366 heterozygous for a splice site and frameshift variant. The cell lines from family 21 are derived
367 from the mother (21m) and the mother's children (21.1 and 21.2) who are heterozygous or
368 homozygous for a *TRMT1* frameshift variant, respectively. The reduction in m²,2G modification
369 in cell lines with homozygous splice site and/or frameshift variants is consistent with the loss of
370 full-length TRMT1 protein expression. The patient cell line from Family 19 is compound
371 heterozygous for the S467L/R323C missense variants. The reduction in m²,2G modification in
372 this cell line indicates that the S467L and R323C variants reduce the activity of TRMT1.

373 No significant change in m²,2G modification was detected in the patient 4 cell line,
374 which is compound heterozygous for the Q332R missense and a splice site variant (Figure 5A
375 and B, lane 8, quantified in Figure 5C and D). These results suggest that the combination of these
376 two *TRMT1* alleles produces enough active protein to maintain m²,2G modification in tRNA-
377 Met-CAU and mt-tRNA-Ile-GAU. This finding is consistent with our observation that the patient
378 4 cell line exhibits comparable levels of TRMT1 protein as wildtype human cells (Figure 4).

379

380 **TRMT1 protein variants exhibit defects in reconstituting m²,2G modification in cells**

381 We next used a TRMT1-knock out (KO) cell line derived from 293T human embryonic
382 kidney cells to test TRMT1 variants for their ability to rescue m²,2G formation *in vivo*. The
383 TRMT1-KO line lacks TRMT1 protein expression resulting in the absence of m²,2G
384 modifications in all tested tRNAs (6). The TRMT1-deficient 293T cell line allowed us to further
385 characterize the functionality of TRMT1-ID variants, including variants for which patient cell
386 lines were not available. As a comparison, we also tested a TRMT1-S363L missense variant

387 present as a minor allele in certain populations and is predicted to be non-pathogenic based upon
388 mutation screenings (18).

389 Using transient transfection of plasmid constructs, we expressed either WT-TRMT1 or
390 TRMT1 variants in the TRMT1-KO cell line. We then assessed for rescue of m²,2G formation in
391 tRNA-Met-CAU or mt-tRNA-Ile-GAU using the primer extension assay described above. As
392 expected, wildtype 293T cells transfected with vector alone exhibited an RT block at position 26
393 of tRNA-Met-CAU and mt-tRNA-Ile-GAU indicative of the m²,2G modification (Figure 6A
394 through D, lane 1). The m²,2G modification was absent in tRNA-Met-CAU and mt-tRNA-Ile-
395 GAU from the vector-transfected TRMT1-KO cell line leading to read-through to the next RT
396 block (Figure 6A through D, lane 2). Re-expression of wildtype (WT)-TRMT1 in the TRMT1-
397 KO cell line was able to restore m²,2G formation (Figure 6A through D, lane 3). Due to
398 incomplete transfection efficiency which caused variable TRMT1 expression, the level of m²,2G
399 modification was increased in the TRMT1-KO cell line but not completely rescued to the level
400 of the original WT cell line.

401 Using this assay, we found that the TRMT1-Q332R missense variant from Family 4
402 exhibited similar reconstitution of m²,2G formation as wildtype TRMT1 (Figure 6A and B, lane
403 5, quantified in Figure 6E and F). The wildtype activity of the Q332R variant is consistent with
404 the wildtype levels of m²,2G modification detected in the tRNAs of the patient cell line derived
405 from Family 4 (Figure 6A-D). The TRMT1-S363L minor variant also retained the ability to
406 reconstitute m²,2G formation similar to that observed in WT-TRMT1 (Figure 6C and D, lane 5,
407 quantified in Figure 6E and F).

408 Notably, we found that the TRMT1-D231N variant from Family 14 and TRMT1
409 truncation variant (1-398) from Family 2 were greatly reduced in their ability to reconstitute

410 m²,2G formation in the TRMT1-KO cell line (Figure 6A and 6B, lanes 4 and 6, quantified in
411 Figure 6E and F). The reduced activity of the TRMT1-D231N variant from Family 14 is
412 consistent with the drastically reduced m²,2G levels in patient cells homozygous for the D231N
413 variant (Figure 5). We also found that the R169P missense variant from Family 9 and TRMT1
414 L465 deletion variant from Family 3 exhibited defects in reconstituting m²,2G formation in
415 TRMT1-KO cell lines (Figure 6C and 6D, lanes 4 and 6, quantified in Figure 6E and F). These
416 results suggest that individuals homozygous for these variants are likely to be deficient in m²,2G
417 modifications.

418

419 **TRMT1 variants exhibit defects in tRNA binding**

420 We next investigated the interaction between TRMT1 variants and tRNAs to dissect the
421 molecular defects associated with individual TRMT1-ID variants. We have previously shown
422 that human TRMT1 displays a stable interaction with substrate tRNAs that are targets for m²,2G
423 modification (6, 17). Using this system, we expressed a FLAG-tagged version of the TRMT1
424 variants in 293T human embryonic kidney cells followed by affinity purification and analysis of
425 copurifying RNAs. Sample recovery of copurifying RNAs was confirmed through the spike-in
426 addition of a synthetic RNA that served as a recovery control (RC). We analyzed the same set of
427 TRMT1 variants as in Figure 6. Immunoblotting confirmed the expression and purification of
428 each TRMT1 variant on anti-FLAG resin (Figure 7A, B).

429 In the control purification from vector-transfected cells, we detected only background
430 contaminating 5.8S and 5S ribosomal RNAs (5.8S and 5S; Figure 7C, lanes 7, 8; Figure 7D, lane
431 6). In contrast, the purification of WT-TRMT1 resulted in the enrichment of tRNAs along with
432 rRNAs as we have previously shown (Figure 7C, lane 9; Figure 7D, lane 7). In contrast to WT-

433 TRMT1, we found that the TRMT1 truncation variant found in Family 2 exhibited defects in
434 binding RNA (Figure 7B, lane 12). Interestingly, we found that the TRMT1-D231N and Q332R
435 variants exhibited increased copurification of tRNAs compared to wildtype TRMT1 while rRNA
436 copurification was decreased (Figure 7C, compare lane 9 to lanes 10 and 11). These results
437 suggest that the D231N and Q332R variants alter the RNA binding specificity of TRMT1 to
438 prefer interaction with tRNAs versus rRNAs.

439 We found that the TRMT1-R169P missense variant from Family 10 and L465 deletion
440 variant found in Family 3 exhibited reduced binding to tRNAs compared to wildtype TRMT1
441 (Figure 7D, lanes 8 and 10). The reduced tRNA binding by the TRMT1-R169P could explain its
442 diminished ability to reconstitute m²,2G formation in cells. The TRMT1-S363L minor variant
443 exhibited similar binding to tRNAs compared to wildtype TRMT1. The wildtype tRNA binding
444 of the TRMT1-S363L variant is consistent with the wildtype activity of this variant in
445 reconstitution assays observed above. Altogether, these findings uncover the molecular effects of
446 ID-associated TRMT1 variants on methyltransferase activity and tRNA binding that underlie
447 deficits in m²,2G modification in patient cells.

448

449 **TRMT1 missense variants reveal distinct functional regions required for TRMT1 activity**

450 To gain insight into the functional effects, we mapped the *TRMT1* variants onto a
451 predicted human TRMT1 structure generated through AlphaFold (19). The hypothesized
452 structure of human TRMT1 was aligned with the solved structure of Trm1 bound to SAM from
453 the archaea *Pyrococcus horshiki* (20). Based upon this structural alignment, human TRMT1 is
454 predicted to fold into two domains coinciding with the SAM-dependent methyltransferase
455 domain and a C-terminal domain unique to Trm1 enzymes (Figure 8, N-terminal domain in blue,

456 C-terminal domain in yellow). The N-terminal domain of TRMT1 forms a putative active site for
457 binding of the SAM methyl donor and a pocket for accommodating the G26 nucleotide that
458 undergoes methylation (Figure 8, red dash circle denotes active site, SAM denoted in green).

459 Notably, the D231N and R323C variants are situated near the predicted G26 pocket
460 (Figure 8, D231N and R323C). As shown above, the D231N and R323C variants are defective in
461 tRNA modification activity but retain similar levels of tRNA binding as wildtype TRMT1. This
462 result is consistent with these variants perturbing G26 substrate positioning in the active site and
463 preventing catalysis without a major effect on overall tRNA recognition and binding. Similar to
464 the R323C and D231N variants, the R169P variant lies nearby the putative G26 binding pocket
465 of TRMT1. However, in contrast to the R323C and D231N variants, the R169P variant is
466 predicted to disrupt the formation of a conserved alpha helix within the active site that is likely to
467 cause broader changes in the N-terminal domain. This drastic alteration in structure is consistent
468 with the R169P variant exhibiting defects in both tRNA modification activity and tRNA binding
469 (Figure 7).

470 The C348R, L465-R466deletion, and S467L variants lie within the C-terminal domain
471 that is unique to the Trm1 enzyme family. The C348R variant resides within the C1 subdomain.
472 In *Pyrococcus horshiki* Trm1, the C1 subdomain makes numerous hydrophobic contacts with the
473 N-terminal domain (20). Thus, the C348R variant could alter the folding of the C1 subdomain
474 thereby impacting the N-terminal catalytic domain. The L465R and S467L variants lie within a
475 predicted alpha helix of the C3 subdomain, which faces across from the active site (Figure 8,
476 C3). The C3 subdomain exhibits similarity with subdomains in phenylalanine tRNA synthetase
477 that bind the anticodon region of tRNA-Phe (21). This similarity suggests that the C3 subdomain
478 of TRMT1 could form additional contacts with the tRNA anticodon domain during substrate

479 binding. Consistent with this role, we have found that the L465R variant disrupts tRNA binding
480 and reconstitution of tRNA modification activity. Altogether, the TRMT1 missense variants
481 reveal distinct functional activities linked to specific subdomains within the TRMT1 polypeptide.

482

483 **Depletion of *Trmt1* in zebrafish causes developmental and behavioral perturbations**

484 To investigate the loss of TRMT1 function *in vivo*, we used zebrafish as a model and
485 employed the CRISPR/Cas9 method to generate biallelic mutations using three guide RNAs
486 targeting the functional domain. We analyzed the phenotype in the F0 (founder) generation
487 because our previous data suggest that F0 knockouts recapitulate phenotypes from the stable
488 genetic knockouts (22, 23). RT-qPCR results found significant downregulation of *trmt1* mRNA
489 expression in F0 knockouts (Figure 9A). We then used liquid chromatography-mass
490 spectrometry to measure m²,2G levels in whole larvae or head-only samples from Cas9-injected
491 control and *trmt1* F0 knockout larvae. Consistent with the depletion of *Trmt1*, the levels of
492 m²,2G modification were reduced in both whole larvae or head-only samples from *trmt1* F0
493 knockout larvae (Figure 9B). In contrast, no significant difference was detected in the levels of
494 the 1-methyladenosine (m¹A) modification, which is another widespread tRNA modification
495 (Figure 9C). We performed morphological phenotyping and found that *trmt1* F0 fish exhibited
496 reduced head, eye, and body sizes (Figure 9D to G). These results indicate that depletion of
497 *Trmt1* and reduction in m²,2G modifications is sufficient to induce a general developmental
498 delay in zebrafish.

499 Given that many affected individuals with pathogenic *TRMT1* variants exhibit behavioral
500 phenotypes, zebrafish larvae were used to identify distinct swimming patterns in response to
501 light and dark conditions. Therefore, we conducted a behavioral assay by exposing zebrafish

502 larvae to alternating 30-minute light and dark cycles. Interestingly, we found that the mutant
503 larvae displayed increased overall locomotor activity in both light and dark cycles (Figure 9H to
504 J). During the dark cycles, the F0 knockouts showed similar activity to control fish in the initial
505 10 minutes (black bars in Figure 9H, quantified in Supplementary Figure 4A), but sustained
506 higher activity in the remaining 20 minutes (green bars in Figure 9H, quantified in Figure 9K),
507 suggesting a hyperactivity-like behavior. Additionally, the mutants showed a pronounced
508 increase in movement during the first minute of light cycles (Figure 9L), potentially indicating
509 light-induced seizure-like behavior (22). Furthermore, a decreased acoustic-evoked behavioral
510 response (AEBR) was observed in the *trmt1* knockout larvae (Supplementary Figure 4B),
511 suggesting impaired hearing. The phenotype analysis in F0 knockouts recapitulates a subset of
512 patient symptoms, demonstrating a conserved role for Trmt1 in zebrafish.

513

514 **Discussion**

515 In this study, we identify and characterize novel variants in *TRMT1* that impact mRNA
516 splicing, protein levels and/or enzymatic activity. Our studies define a core set of phenotypic
517 features universally associated with pathogenic *TRMT1* variants that encompasses intellectual
518 disability, global developmental delay, and facial dysmorphism. While no major intrafamilial
519 phenotypic variability was observed, the present cohort exhibited remarkable interfamilial
520 phenotypic variability characterized by a spectrum of behavioral, morphological, and
521 physiological features. These findings are significant by indicating that TRMT1 is required for a
522 common set of developmental and neurological pathways with further clinical outcomes
523 determined by genetic and environmental factors specific to each family.

524 Depletion of Trmt1 and m2,2G modifications in zebrafish results in developmental and
525 behavior phenotypes that resemble certain core features of TRMT1-associated syndromes in
526 human patients. Importantly, these findings demonstrate that TRMT1 homologs play a conserved
527 role in the proper development and function of the central nervous system in vertebrates. The
528 future generation of zebrafish strains that are biallelic for the pathogenic variants discovered here
529 will allow us to further dissect the spectrum of phenotypes in an isogenic background.

530 Overall, our findings support a model in which loss of m2,2G modifications due to a
531 decrease in functional TRMT1 protein and/or activity results in downstream perturbations in
532 molecular and cellular processes that cause neurodevelopmental phenotypes. Moreover, we find
533 that the penetrance of the core phenotypic effects can depend on the severity of the variant on
534 TRMT1 function in tRNA modification as well as the specific type of change caused by the
535 TRMT1 variant. For example, we find that TRMT1 variants can induce aberrant splicing, but with
536 distinct outcomes that could differentially impact the functional levels of TRMT1. In addition to
537 loss-of-function splice isoforms, there could be aberrant splice variants that exert dominant
538 negative effects by coding for TRMT1 products that bind tRNA substates without modifying them
539 or exhibit gain-of-function properties. It will also be interesting to determine if any of the splice
540 variants serve regulatory roles that are perturbed by the *TRMT1* variants.

541 Since TRMT1 is known to modify numerous tRNA targets, each tRNA could be affected
542 to a different extent by a *TRMT1* variant that could account for the variable phenotypic outcomes.
543 For example, the compound heterozygous S467L/R323C variant appears to more severely impact
544 the modification of mt-tRNA-Ile compared to cytoplasmic tRNA-Met. In addition, the TRMT1
545 protein variants that affect catalytic activity without impacting tRNA binding could retain RNA
546 chaperone functions that are completely abrogated for other TRMT1 protein variants. Future

547 studies that profile the global modification status and levels of individual tRNAs in each patient
548 would shed light on the differential effects of each TRMT1 variant.

549 The variable clinical presentations and age of onset of individuals with similar genotypes
550 support the existence of additional, currently unidentified modifying variants in other genes
551 besides TRMT1. Future studies will focus on identifying genetic modifiers in this cohort that
552 could reveal the biological pathways and processes that are connected to TRMT1 function.
553 Importantly, the functional demonstration of pathogenicity for so many variants in multiple
554 families across the world indicates that *TRMT1* should be included in genetic registries as a key
555 disease gene linked to developmental brain disorders with autosomal recessive Mendelian
556 inheritance (24).

557

558 **MATERIAL AND METHODS**

559 **Recruitment of research subjects**

560 The 24 families with bi-allelic *TRMT1* variants were identified using the GeneMatcher
561 platform (25) and data sharing with collaborators. Informed consent for genetic analyses was
562 obtained from all subjects. Clinical details of the cohort were obtained by the follow-up of
563 affected individuals. Seizure description is reported in line with the most recent ILAE guidance
564 (26). Parents and legal guardians of all affected individuals gave their consent for the publication
565 of clinical and genetic information according to the Declaration of Helsinki, and the study was
566 approved by The Research Ethics Committee Institute of Neurology University College London
567 (IoN UCL) (07/Q0512/26) and the local Ethics Committees of each participating center. Consent
568 has been obtained from a subset of families to publish medical photographs and video
569 examinations. Brain magnetic resonance imaging (MRI) scans were obtained from 12 affected

570 individuals and were reviewed by an experienced team of pediatric neuroradiologists. Cerebellar
571 atrophy, callosal thinning, and calvarial deformities were defined using standardised criteria (27-
572 29). Facial photographs and/or videos of 13 patients from 10 families were reviewed and their
573 dysmorphic features were described using terminology recommended by Elements of
574 Morphology. Where no term was available for a dysmorphic feature seen in a patient, HPO
575 terminology was used instead.

576

577 **Variant identification and NGS data interpretation**

578 Single-nucleotide variations (SNVs) were identified by Whole Exome Sequencing (WES) or
579 Whole Genome Sequencing (WGS) in all individuals. Exomes or genomes were captured and
580 sequenced on Illumina sequencers as described elsewhere (30) in Macrogen, Korea or at
581 collaborating centers (see Table 2). The bioinformatics filtering strategy included screening for only
582 exonic and donor/acceptor splicing variants. Rare variations present at a frequency above 1% in
583 GnomAD v.3.1.2 (<https://gnomad.broadinstitute.org/>) or present from exomes or genomes within
584 datasets from UK Biobank and UK 100,000 genome project or from internal research databases
585 (e.g., Queen Square Genomics and UCL SYNAPS Study Group) were excluded. Candidate variants
586 were then inspected with the Integrative Genomics Viewer and then confirmed by Sanger
587 sequencing in all the families. Sequence variants in the *TRMT1* gene were described according to the
588 recommendations of HGVS and are based on the reference sequence NM_001136035. Sequence
589 candidate variants were interpreted according to ACMG Guidelines (31).

590

591 **Cell culture of primary dermal fibroblasts**

592 Primary dermal fibroblasts were obtained from a skin biopsy of subjects. Fibroblasts
593 were cultured in Dulbecco's modified Eagle medium (DMEM; Thermo Fisher Scientific)
594 supplemented with 10% fetal bovine serum (FBS; GE Healthcare) and penicillin-streptomycin
595 (100 U/mL and 100 mg/mL, respectively; Thermo Fisher Scientific). For all experiments, the
596 same passage number of subject and control fibroblasts was used. Primary fibroblasts were
597 regularly tested for mycoplasma contamination and confirmed to be mycoplasma free.

598

599 **Cell culture of primary lymphoblasts**

600 Lymphoblastoid cell lines (LCLs) are generated by Epstein-Barr virus (EBV)
601 transformation of the B-lymphocytes within the peripheral blood lymphocyte (PBL) of patients.
602 LCLs were cultured in cells in RPMI 1640 medium (Thermo Fisher Scientific) supplemented
603 with 10% fetal bovine serum (FBS; GE Healthcare) and penicillin-streptomycin (100 U/mL and
604 100 mg/mL, respectively; Thermo Fisher Scientific) in standing flasks at 37°C and 5% CO₂ for
605 several days until adhering to the flask and reaching a desired cell count.

606

607 **Minigene splicing assay**

608 Computational assessment of splicing effects used SpliceSiteFinder-like, MaxEntScan,
609 NNSplice, and GeneSplicer embedded in Alamut Visual Plus v1.6.1 (Sophia Genetics, Bidart,
610 France), as well as SpliceAI 10K and AbSplice as included in SpliceAI Visual (32).

611 RNA studies of variants were conducted following established protocols with some
612 modifications (33, 34) using three constructs with variants annotated to NM_001136035.4. In

613 brief, the first construct comprised a 1002 bp region spanning introns 2 to 5, encompassing the
614 c.255-1G>T, c.310+5G>C, c.311-1G>A, and c.454-1G>C variants. The second construct
615 involved a 416 bp segment spanning introns 8 to 10 to assay splice effects of the c.1107-1G>A
616 variant. Finally, the third construct covered a 446 bp region spanning intron 10 to exon 12,
617 targeting the c.1194G>A variant. These regions were amplified from genomic DNA obtained
618 from the probands and a healthy control using primers containing specific restriction sites
619 (Supplementary Table 7). The PCR fragments were ligated between exons A and B of the
620 linearized pSPL3-vector following digestion with restriction enzymes. The recombinant vectors
621 were transformed into DH5 α competent cells (NEB 5-alpha, New England Biolabs, Frankfurt,
622 Germany), plated and incubated overnight. Following colony PCR with SD6 F (Supplementary
623 Table 7) and the target-specific reverse primer, the wild-type and mutant-containing vector
624 sequences were confirmed by Sanger sequencing and transfected into HEK 293T cells (ATCC,
625 Manassas, VA, USA). 2 μ g of the respective pSPL3 vectors was transiently transfected using 6
626 μ L of FuGENE 6 Transfection Reagent (Promega, Walldorf, Germany). An empty vector and
627 transfection negative reactions were included as controls. The transfected cells were harvested 24
628 hours after transfection. Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden,
629 Germany). cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit
630 (Applied Biosystems, Waltham, MA, USA) following the manufacturer's protocols. cDNA was
631 PCR amplified using vector-specific SD6 F and SA2 R primers (Supplementary Table 7). The
632 amplified fragments were visualized on a 1% agarose gel. cDNA amplicons were TA cloned
633 following standard protocols with the pCR2.1 vector kit (ThermoFisher, Darmstadt, Germany)
634 and Sanger sequenced. Fragment analysis was performed for construct 1 with FAM-labelled SD6
635 F and SA2 R primers using the 3500xL Genetic Analyzer (Thermo Fisher Scientific, Waltham,

636 MA, USA). Analysis was performed using GeneMapper Software 5 (Applied Biosystems).
637 Analysis and cataloging of protein-coding versus non-protein coding transcripts and their
638 expression was performed using Ensembl and GTEx Portal. Non-coding transcripts were
639 excluded in calculations to determine the average peak area for construct 1. The percentage of
640 each band was calculated using fragment analysis (Supplementary Figure 2, Supplementary Data
641 1).

642

643 **Immunoblotting**

644 For protein immunoblotting, fibroblast or lymphoblast cells were resuspended in
645 hypotonic lysis buffer for protein extraction as noted previously (17, 35, 36). Cell extracts were
646 boiled at 95°C for 5 minutes followed by fractionation on NuPAGE Bis-Tris polyacrylamide gels
647 (Thermo Scientific). Separated proteins were transferred to Immobilon FL polyvinylidene
648 difluoride (PVDF) membrane (Millipore) for immunoblotting. Membrane was blocked by
649 Odyssey blocking buffer for 1 hour at room temperature followed by immunoblotting with the
650 following antibodies: anti-TRMT1 (sc-373687, Santa Cruz Biotechnology), anti-FLAG epitope
651 tag (L00018; Sigma) and anti-actin (L00003; EMD Millipore). Proteins were detected using a
652 1:10,000 dilution of fluorescent IRDye 800CW goat anti-mouse IgG (925-32210; Thermofisher).

653

654 **RNA analysis**

655 RNA was extracted using TRIzol LS reagent (Invitrogen). For primer extension analysis,
656 1.5 µg of total RNA was pre-annealed with 5'-32P-labeled oligonucleotide and 5x hybridization
657 buffer (250 mM Tris, pH 8.5, and 300 mM NaCl) in a total volume of 7 µl. The mixture was
658 heated at 95°C for 3 min followed by slow cooling to 42°C. An equal amount of extension mix

659 consisting of avian myeloblastosis virus reverse transcriptase (Promega), 5x AMV buffer and 40
660 μ M dNTPs was added. The mixture was then incubated at 42°C for 1 hour and loaded on 18 to
661 20% 7M urea denaturing polyacrylamide gels. Gels were exposed on a phosphor screen and
662 scanned on a Sapphire Biomolecular Imager (Azure Biosystems). Quantification was performed
663 using NIH ImageJ software followed by statistical analysis using GraphPad Prism. Primer
664 extension oligonucleotide sequences were previously described (Dewe et al., 2017).

665

666 **Transient transfection of 293T cells**

667 The 293T TRMT1-KO cell line has been described previously (6). 293T cells were
668 transfected via calcium phosphate transfection method (37). Briefly, 2.5×10^6 cells were seeded
669 on 100×20 mm tissue culture grade plates (Corning) followed by transfection with 10 μ g of
670 plasmid DNA. Cells were harvested 48 h later by trypsin and neutralization with media, followed
671 by centrifugation of the cells at $700 \times g$ for 5 min followed by subsequent PBS wash and a
672 second centrifugation step.

673

674 **Protein-RNA purifications.**

675 Protein was extracted using hypotonic lysis and high salt immediately after cells were
676 harvested. Cell pellets were resuspended in 0.5 ml of hypotonic lysis buffer (20 mM HEPES pH
677 7.9, 2 mM $MgCl_2$, 0.2 mM EGTA, 10% glycerol, 0.1 mM PMSF, 1 mM DTT) per 100×20 mm
678 tissue culture plate. Cells were kept on ice for 5 min and then subjected to 3 freeze-thaw cycles
679 in liquid nitrogen and a 37 °C water bath. NaCl was then added to the extracts at a concentration
680 of 0.4 M, incubated on ice for 5 mins, and centrifuged at $14,000 \times g$ for 15 min at 4 °C. After

681 centrifugation, 500 μ l of supernatant extract was removed and 500 μ l of Hypotonic Lysis buffer
682 supplemented with 0.2% NP-40 was added to obtain 1,000 μ l of extract.

683 FLAG-tagged proteins were purified by incubating whole cell lysates from the
684 transiently-transfected cell lines with 50 μ l of Anti-DYKDDDDK Magnetic Beads (Clontech) for
685 two hours at 4 °C. Magnetic resin was washed three times in hypotonic wash buffer (20 mM
686 HEPES pH 7.9, 2 mM MgCl₂, 0.2 mM EGTA, 10% glycerol, 0.1% NP-40, 0.2 M NaCl, 0.1 mM
687 PMSF, and 1 mM DTT). SDS-PAGE sample buffer was added to one portion of resin and
688 purified proteins were fractionated on a NuPAGE Bis-Tris polyacrylamide gel (ThermoFisher).
689 The gel was transferred to Immobilon-FL Hydrophobic PVDF Transfer Membrane (Millipore
690 Sigma) with subsequent immunoblotting against the FLAG tag as noted above.

691 RNA from input and purified samples were extracted using RNA Clean & Concentrator-5
692 columns (Zymo Research). RNA extraction followed TRIzol LS RNA extraction protocol
693 (Invitrogen). RNA was resuspended in 5 μ l of RNase-free water and loaded onto a 10%
694 polyacrylamide, 7 M urea gel. The gel was then stained with SYBR Gold nucleic acid stain
695 (Invitrogen) to visualize RNA.

696

697 **Ethics Statement and Zebrafish Husbandry**

698 All experimental animal care was performed in accordance with institutional and NIH
699 guidelines and regulations. Zebrafish (*Danio rerio*) were raised and maintained in an Association
700 for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility at
701 the Oklahoma Medical Research Foundation (OMRF) under standard conditions. All
702 experiments were conducted as per protocol (22-76) approved by the Institutional Animal Care
703 Committee (IACUC) of OMRF.

704

705 **Generation of *trmt1* F0 knockout zebrafish**

706 We followed previously described methods to generate *trmt1* F0 knockouts (PMID:
707 38031187). Briefly, three guide sequences were designed using the CRISPOR tool, and guide
708 RNAs (gRNAs) were chemically synthesized (Synthego Inc., CA, USA). A 6 μ L mixture
709 containing 1 μ L of 40 μ M Cas9-NLS protein (UC Berkeley QB3 Macrolab, Berkeley, CA,
710 USA), 500 ng of each gRNA (in 3 μ L), and 2 μ L of 1 M potassium chloride was injected into
711 one-cell stage wild-type (WT) embryos. As a control, WT embryos were injected with a mixture
712 containing Cas9 protein but lacking gRNA. The gRNA target sequences are listed in
713 Supplementary Table 8.

714

715 **RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)**

716 Total RNA was extracted from either whole larvae or head-only samples using TRIzol
717 Reagent (Thermo Fisher Scientific, USA) and purified with the RNA Clean and Concentrator-5
718 kit (Zymo, USA) according to the manufacturer's instructions. Larvae at 4 dpf were anesthetized
719 in 168 mg/L Tricaine methanesulfonate/MS-222 (Sigma-Aldrich, MO, USA) before head
720 dissection. Each experimental group consisted of three biological replicates, with six larvae
721 pooled per replicate, collected randomly at 4 days post-fertilization (dpf). cDNA was synthesized
722 using the iScript RT Supermix (Bio-Rad, CA, USA) and used as a template for RT-qPCR with
723 SYBR Green Supermix (Thermo Fisher Scientific, CA, USA) on the Light Cycler® 96 System
724 (Roche, CA, USA). All RT-qPCR reactions were performed in biological triplicates with
725 technical triplicates. The *18S* gene was used as a reference gene. Primer sequences for RT-qPCR

726 are listed in Supplementary Table 8. Cycle threshold (Ct) values were analyzed in Microsoft
727 Excel, and relative gene expression was quantified using the $2^{(-\Delta\Delta Ct)}$ method.

728

729 **Morphological phenotyping**

730 To assess morphological phenotypes, zebrafish larvae were randomly selected at 4 dpf
731 for imaging. Larvae were manually positioned in 2% methylcellulose (Sigma, USA) under a
732 stereomicroscope and imaged. Head, eye, and body measurements were obtained directly from
733 scale-calibrated images using ImageJ software (NIH). Head size was determined by measuring
734 the distance from the tip of the snout to the end of the operculum (gill cover). Eye size was
735 measured as the eye diameter, and body size was measured as the length from the tip of the snout
736 to the end of the tail. All bright-field images were captured using a Nikon DS-Fi2 high-definition
737 camera mounted on a Nikon SMZ18 stereomicroscope (Nikon, Japan) with auto-Z-stacking
738 capability.

739

740 **Behavioral assay**

741 All behavior tests were performed at room temperature (RT), as previously described
742 (22). In brief, to conduct the LDT test, larvae at 4 dpf were delicately moved into individual
743 wells of a 96-well plate, each containing 150 μ L of embryo water. The following day, the plate
744 was placed into a Noldus chamber, and locomotion activity was recorded using the DanioVision
745 system, which runs EthoVision XT software (Noldus Information Technology, Leesburg, VA,
746 USA). Specifically, larvae at 5 dpf were allowed a 30-minute habituation period in the light,
747 followed by alternating 30-minute dark and light periods for two cycles. The locomotion activity
748 of the larvae was measured in terms of distance traveled (in millimeters) per minute. The

749 recorded values for each minute were then plotted using GraphPad Prism (GraphPad Software,
750 San Diego, CA, USA). Larvae at 6 dpf were subjected to an acoustic-evoked behavioral response
751 (AEBR) test using the Zebrabox (ViewPoint Life Sciences, Montreal, Canada). For AEBR
752 quantification, the number of responses to 12 stimuli for each larva was calculated as a
753 percentage of the total responses. Values were plotted using box and whisker plot generated by
754 GraphPad Prism. Error bars indicate the range from the minimum to the maximum values, with
755 the median value represented by the line in the center of the box.

756

757 **Statistics**

758 The statistical analysis was conducted using GraphPad Prism. Data are presented as
759 indicated in figure legends. For all analyses, the significance level was set at 0.05. Significance
760 was determined using a two-tailed unpaired Student's *t*-test with Welch's correction for two
761 comparisons, as detailed in the figure legends. *P*-values were represented as follows: not
762 significant (ns) $p \geq 0.05$, $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$.

763

764 **Acknowledgements**

765 The authors would like to thank the affected individuals and their families for their
766 support of this study. One of the authors of this publication (ZT) is a member of the European
767 Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-
768 ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. BV
769 is a member of the European Reference Network on Rare Congenital Malformations and Rare
770 Intellectual Disability (ERN-ITHACA) [EU Framework Partnership Agreement ID: 3HP-HP-
771 FPA ERN-01-2016/739516].

772

773 **Funding**

774 The research in this manuscript was supported by NIH GR530882 to D.F. Studies
775 performed in the lab of G.K.V was funded by NIH R24OD034438. The clinic-genetic research
776 was funded in part, by the Wellcome Trust (WT093205MA, WT104033AIA). This study was
777 funded by the Medical Research Council (MR/S01165X/1, MR/S005021/1, G0601943), The
778 National Institute for Health Research University College London Hospitals Biomedical
779 Research Centre, Rosetrees Trust, Ataxia UK, Multiple System Atrophy Trust, Brain Research
780 United Kingdom, Sparks Great Ormond Street Hospital Charity, Muscular Dystrophy United
781 Kingdom (MDUK), Muscular Dystrophy Association (MDA USA) and the King Baudouin
782 Foundation. SE and HH were supported by an MRC strategic award to establish an International
783 Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. B.V. was
784 supported by the Deutsche Forschungsgemeinschaft (DFG) DFG VO 2138/7-1 grant 469177153.
785 J.S. is supported by Cancer Research UK and University College London. A.F. and S.C. are
786 supported by Health & Care Research Wales, Epilepsy Research UK, PhD Swansea University
787 funding.

788

789 **Competing interests**

790 M.M.M and A.C are employees of GeneDx, LLC. R.S. is on the advisory board for Guide
791 Genetics and Egetis Pharmaceuticals.

792

793 **Data availability**

794 The data that supports the findings of this study are available within the paper and in the
795 supplementary material. Whole-exome sequencing data are not publicly available due to privacy
796 or ethical restrictions. The novel *TRMT1* variants reported in this manuscript were submitted to
797 the LOVD database (<https://databases.lovd.nl/shared/genes/TRMT1>), with the LOVD variant
798 IDs: # 0000944528, # 0000944622, # 0000944624, # 0000944625,
799 # 0000944626, # 0000944640, # 0000944641, # 0000944642, # 0000944643, # 0000944646, #
800 0000944620, # 0000944621, # 0000944647, # 0000944709, # 0000944708, # 0000944710, #
801 0000944712, # 0000944713, # 0000944714, # 0000944715, # 0000944716, #0000959740,
802 #0000959741, #0000959742, #0000959743.

803

804 **Author contributions**

805 Conceptualization: S.E., A.E.F., R.M., D.F.; Data Curation: S.E., C.D., C.L., K.Z., S.J.L, R.Q.L,
806 I.K., D.F.; Formal Analysis: S.E., C.D., C.L., K.Z., R.Q.L, I.K. D.O., J.S., K.M. B.V., D.F.;;
807 Methodology: S.E., B.V., D.F.; Funding Acquisition: B.V., G.V., H.H., D.F. ; Investigation: all
808 authors; Recruitment, Clinical, and Diagnostic Evaluations: R.K., F.J., J.R.A., T.S., C.L., M.J.,
809 F.T., M.I.V.P., R.S., G.Y., M.O., J.F., E.H.G., C.P., B.I., C.P., S.H., D.S., V.B., K.P., D.W.,
810 M.K., N.R., A.T., H.M., C.F., S.T.B., A.B., N.C., G.L., S.C., Z.T., T.D.H., G.R., T.M., J.R.,
811 E.A., M.Z., R.A., H.G., P.N., N.C, M.Z., J.G.G., D.G.C., D. P., A.R., I.S.A., G.O., A.E.F.
812 Writing-original draft: S.E., C.D., C.L., K.Z., R.Q.L, I.K., D.O., J.S., K.M., B.V., D.F.; Writing-
813 review and editing: all authors.

814

815 Table 1. Clinical Details

	Family 1		Family 2		Family 3		
TRMT1 variant(s) (NM_001136035)	c.454-1G>C p.(Cys86Glnfs*24)		c.1194G>A (p.Trp398*)		c.1394_1396delTGC (p.Leu465_Arg466delinsTrp)		
Development							
Speech/language delay	Yes	Yes	Yes	Yes	Yes	N/A	N/A
Motor delay	Yes	Yes	Yes	Yes	Yes	N/A	N/A
ID	Moderate	Mild	Severe-profound	Mild	Moderate	N/A	N/A
Behaviour	Yes (poor concentration)	Yes (ADHD)	Yes (Hyperactive and aggressive)	No	No	N/A	N/A
Clinical Features							
Microcephaly/Macrocephaly	No	No	N/A	N/A	No	No	Macrocephaly
Hypertonia or Hypotonia	-	-	-	-	-	N/A	N/A
Seizures	-	-	Yes (febrile)	Yes (generalized tonic-clonic)	-	Yes	-
Dysmorphic features	+	+	+	+	-	N/A	+
Investigations							
Abnormal MRI brain	-	-	+	+	-	N/A	N/A
Abnormal EEG	+	+	-	-	N/A	N/A	N/A

816

817

818 Table 1. (Continued)

	Family 4	Family 5	Family 6	Family 7	Family 8
TRMT1 variant(s) (NM_001136035)	c.995A>G (p.Gln332Arg) and c.255-1G>T p.(Cys86Glnfs*24)	c.1107-1G>A p.(Ala370Profs*11) and c.310+5G>C p.(Cys86Glnfs*24)	c.884dup (p.Leu296Profs*24) and c.1042T>C (p.Cys348Arg)	c.209 A>G (p.Asn70Ser) and c.352G>T (p.Asp118Tyr)	c.1107-1G>A p.(Ala370Profs*11) and c.389_390delAA (p.Lys130Argfs*3)
Development					
Speech/language delay	Yes	Yes	Yes	Yes	Yes
Motor delay	Yes	Yes	Yes	No	Yes
ID	Moderate	Yes	Moderate	Yes	N/A
Behaviour	Yes (ASD)	No	Yes (ADHD)	Yes (aggressive and non-social)	Yes (Hyperactive)
Clinical Features					
Microcephaly /Macrocephaly	Microcephaly	No	No	Macrocephaly	No
Hypertonia or Hypotonia	-	Hypotonia	-	-	Hypertonia
Seizures	-	Yes (febrile)	Yes (focal)	-	Yes (generalised)
Dysmorphic features	+	+	+	+	+
Investigations					
Abnormal MRI brain	-	+	+	N/A	+
Abnormal EEG	-	+	+	N/A	+

819

820 Table 1. (Continued)

821

	Family 9	Family 10	Family 11	Family 12
TRMT1 variant(s) (NM_001136035)	c.506G>C (p.Arg169Pro)	c.310+5G>C p.(Cys86Glnfs*24) and c.967C>T (p.Arg323Cys)	c.505C>T (p.Arg169*)	c.1332_1333del (p.Tyr445Leufs*28)
Development				
Speech/language delay	Yes	Yes	Yes	Yes
Motor delay	Yes	N/A	N/A	Yes
ID	Yes	N/A	Yes	Moderate-severe
Behaviour	N/A	Yes (Hyperactive)	Yes	Yes (Poor concentration)
Clinical Features				
Microcephaly /Macrocephaly	No	No	Microcephaly	Microcephaly
Hypertonia or Hypotonia	-	N/A	-	Hypotonia
Seizures	Yes	Yes (generalised febrile)	Yes (febrile)	-
Dysmorphic features	+	+	+	+
Investigations				
Abnormal MRI brain	-	-	+	+
Abnormal EEG	N/A	N/A	-	-

822

823

824

825

826
827
828
829
830 Table 1. (Continued)

	Family 13	Family 14	Family 15	Family 16
TRMT1 variant(s) (NM_001136035)	c.312del (p.Lys105Argfs*25)	c.691G>A (p.Asp231Asn)	c.1332_1333del (p.Tyr445Leufs*28)	c.311-1G>A p.(Cys86Glnfs*24)
Development				
Speech/language delay	Yes	Yes	Yes	Yes
Motor delay	Yes	Yes	Yes	Yes
ID	Moderate	Moderate	Moderate	Moderate-Severe
Behaviour	Yes (Anxiety)	Yes (Hyperactive and self mutilation under-stress)	Yes (Restless, poor autonomy in activities/games)	Yes (ADHD)
Clinical Features				
Microcephaly /Macrocephaly	No	No	Microcephaly	Microcephaly
Hypertonia or Hypotonia	-	-	Hypotonia	Hypertonia
Seizures	Yes (febrile)	Yes (febrile & tonic-clonic)	-	Yes (focal & febrile)
Dysmorphic features	+	+	+	+
Investigations				
Abnormal MRI brain	-	-	+	+
Abnormal EEG	-	+	+	+

831
832 Table 1. (Continued)

	Family 17	Family 18	Family 19	Family 20	
TRMT1 variant(s) (NM_001136035)	c.752_754del (p.Glu251del)	c.310+5G>C p.(Cys86Glnfs*24)	c.1400C>T (p.Ser467Leu) and c.967C>T (p.Arg323Cys)	c.657_688del (p.Gln219Hisfs*22)	
Development					
Speech/language delay	Yes	Yes	Yes	Yes	Yes
Motor delay	Yes	Yes	Yes	Yes	Yes
ID	Mild-moderate	Moderate	Mild	Moderate	Moderate
Behaviour	No	No	No	No	No
Clinical Features					
Microcephaly /Macrocephaly	No	No	Microcephaly	Microcephaly	Microcephaly
Hypertonia or Hypotonia	N/A	-	Hypotonia	-	-
Seizures	-	-	-	Yes (GTC)	Yes (focal & generalised)
Dysmorphic features	+	+	+	+	+
Investigations					
Abnormal MRI brain	+	-	-	+	N/A
Abnormal EEG	-	N/A	-	+	-

833
834 Table 1. (Continued)

	Family 21		Family 22	Family 23		Family 24
TRMT1 variant(s) (NM_001136035)	c.657_688del (p.Gln219Hisfs*22)		c.657_688del p.Gln219Hisfs*22	c.1332_1333del (p.Tyr445Leufs*28)		c.1332_1333del (p.Tyr445Leufs*28)
Development						
Speech/language delay	Yes	Yes	Yes	Yes	Yes	Yes
Motor delay	Yes	Yes	Yes	No	No	Yes
ID	Moderate	Mild-moderate	Moderate	Moderate-severe	Severe	Yes
Behaviour	Yes (Bad temper)	Yes (Bad temper)	Yes (Poor concentration, hyperactivity)	Yes (Bad temper, self-mutilation)	Yes (Anxiety)	Yes (Moderate attention deficit, anxiety)
Clinical Features						
Microcephaly /Macrocephaly	No	No	Microcephaly	No	No	N/A
Hypertonia or Hypotonia	-	-	Hypotonia	-	-	-
Seizures	Yes	Yes	-	Yes (febrile & generalised)	Yes (generalised)	-
Dysmorphic features	+	+	+	+	+	+
Investigations						
Abnormal MRI brain	+	N/A	+	-	-	N/A
Abnormal EEG	-	-	-	-	-	-

835
836


837 Table 1. (Continued)

	Family M300 (Najmabadi <i>et al.</i> , 2011)		Family 9000114 (Davarniya <i>et al.</i> , 2014)			Family 1 (Blaesius <i>et al.</i> , 2018)	Family 2 (Blaesius <i>et al.</i> , 2018)			Zhang <i>et al.</i> , 2020
TRMT1 variant(s) (NM_001136035)	c.657_688 del32 p.Gln219Hisfs*22		c.1332_1333 delGT p.Tr445Leufs*28			c.657_688del32 p.Q219Hfs*22	c.1506+1G>T p.502 Donor			c.967C>T p.Arg323Cys
Development										
Speech/language delay	No	No	Yes	Yes	Yes	Yes	No	No	No	N/A
Motor delay	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No
ID	Moderate	Moderate	Moderate	Mild	Moderate	Moderate	Moderate	Moderate	Moderate	Yes
Behaviour	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Clinical Features										
Microcephaly /Macrocephaly	No	No	No	No	No	Microcephaly	No	Microcephaly	Microcephaly	No
Hypertonia or Hypotonia	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Seizures	No	No	N/A	N/A	N/A	Yes (generalised)	Yes	Yes	Yes	Yes(generalised)
Dysmorphic features	+	+	+	+	+	-	-	-	-	+
Investigations										
Abnormal MRI brain	+	+	-	-	-	+	N/A	N/A	N/A	No
Abnormal EEG	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

838

Abbreviations	
ADHD	Attention deficit hyperactivity disorder
ASD	Autism spectrum disorder
F	Female
GTC	Generalised tonic-clonic
M	Male
m	Months
N/A	Not available
y	Years


839



840

841 **Figure 1. Genetic summary of the reported individuals with homozygous *TRMT1* variants. (A)**
 842 Pedigrees of the 24 families described. Square = male; circle = female; black filled symbol =
 843 affected individual; white symbols = unaffected individuals. Double lines indicate consanguinity.

844 **(B)** Coding exons of the *TRMT1* mRNA with variants noted. **(C)** Schematic indicating the domains
845 of the TRMT1 protein. The red box represents the mitochondrial targeting signal while the blue box
846 indicates the class I *S*-adenosyl-methionine (SAM)-dependent methyltransferase domain. The
847 yellow box indicates a C-terminal bipartite nuclear localization signal (NLS) embedded within a
848 C₃H₁-type zinc finger motif. Variants reported in this study are represented in red, while previously
849 reported variants in black. **(D)** Protein multiple sequence alignment in *TRMT1* orthologues shows
850 level of conservation of the identified missense residues (indicated in dotted line boxes).




851

852


853 **Figure 2. Phenotypic summary of the reported individuals with homozygous *TRMT1* variants.**

854 **(A)** Clinical features of the affected individuals with bi-allelic *TRMT1* variants (ID: intellectual
855 disability). **(B)** Frontal facial photographs of *TRMT1* probands showing the most prominent and
856 frequent dysmorphic features of *TRMT1*-related neurodevelopmental delay. **(C)** Representative
857 neuroimaging features identified in individuals with *TRMT1*-ID. (i) Midsagittal T1-weighted MRI of
858 the brain in a childhood boy (F-5) exhibits global (cerebral and cerebellar) atrophy, posterior
859 thinning of the corpus callosum (arrow), and a mega cisterna magna (asterisk). (ii-iii) Midsagittal
860 (ii) and axial (iii) T1-weighted MRI of the brain in a childhood boy (F-8) shows further,
861 characteristic features of TRMT1-ID, namely: frontotemporal-predominant cerebral and midbrain
862 atrophy with corresponding ventriculomegaly and uniform thinning of the corpus callosum (not all
863 shown). Note is also made of the right posterior positional plagiocephaly, (iv) Midsagittal T1-
864 weighted brain MRI of childhood-old boy (F-23), exhibits cerebellar atrophy, a mega cisterna
865 magna (asterisk), and downsloping of the corpus callosum.




866

867 **Figure 3. *TRMT1* variants induce splicing defects.** Wild-type (WT) and mutant minigenes
 868 were transfected in HEK293T cells and their RNA subjected to RT-PCR. **(A)** RT-PCR for WT
 869 and mutant minigenes showed complex splicing patterns. We obtained sequencing validation for
 870 all except amplicon 2. The presence of additional bands in the WT is attributed to alternative
 871 splicing and was quantified in Supplementary Table 5. The only protein coding transcript
 872 expressed in the brain includes exons 3-5 that has been eliminated or reduced due to the four
 873 variants. The upper left panel shows the RT-PCR agarose gel with the splicing schematic shown
 874 for each band to the right. The variant schematic is shown below. Sanger sequencing results of
 875 the RT-PCR showing the correctly spliced WT with the deleterious variant effect, exon skipping,
 876 as shown by the presence of only pSPL3 vector. The dotted box represents the short version of
 877 exon 5. **(B)** RT-PCR of the c.1107-1G>A results in loss of the native splice acceptor site and
 878 cryptic splice activation leading to loss of a G and a frameshift. The left panel shows the RT-
 879 PCR agarose gel with the splicing schematic shown for each band to the right. Exon 10 with 1 bp
 880 deletion is represented with a dotted line corresponding to the position of the single bp deletion.
 881 **(C)** RT-PCR of the c.1194G>A variant leads to a frameshift due to exon skipping of exons 11
 882 and 12 leading to a frameshift. Asterisks represent assay artifacts. The left panel shows the RT-
 883 PCR gel with the splicing schematic shown to the right. Assay design captured part of exon 12
 884 that was correctly spliced in the WT control.




885

886 **Figure 4. *TRMT1* gene variants cause changes in TRMT1 protein levels.** (A) Representative
 887 immunoblot of the indicated proteins from fibroblast cell lines derived from control (C1) or
 888 affected patients. (B, C) Quantification of TRMT1 levels relative to the control fibroblast cell
 889 line after normalization to actin. N=3. (D) Representative immunoblot of TRMT1 and actin from
 890 lymphoblast cell lines (LCLs) derived from control wildtype (C2) or affected patients. (E)
 891 Quantification of TRMT1 levels in LCLs after normalization to actin. N=3. Error bars represent
 892 standard deviation from the mean. Statistical analysis was performed using one-way ANOVA.
 893 *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P < 0.0001; ns, non-significant, P > 0.05.




894

895 **Figure 5. Patient cells with biallelic *TRMT1* variants exhibit a reduction in m2,2G**
 896 **modifications in tRNAs.** (A, B) Representative gels of primer extension assays to monitor the
 897 presence of m2,2G in tRNA-Met-CAU and mt-tRNA-Ile-GAU from the indicated cell lines.
 898 m3C₂₀, 3-methylcytosine; m2,2G₂₆, dimethylguanosine; m1G₉, 1-methylguanosine; >, labeled
 899 oligonucleotide used for primer extension; *, background signal. (C through F) Quantification
 900 of m2,2G formation by primer extension for the indicated tRNAs. N=3. Error bars represent
 901 standard deviation from the mean. Statistical analysis was performed using one-way ANOVA.
 902 For (C) and (D), the means of each column was compared to the Control 1 cell line. For (E) and
 903 (F), the means of each column was compared to the Control 2 cell line. *P ≤ 0.05; **P ≤ 0.01;
 904 ***P ≤ 0.001; ****P < 0.0001; ns, non-significant, P > 0.05.




905

906 **Figure 6. TRMT1 variants exhibit defects in reconstitution of tRNA modification activity in**
 907 **human cells. (A through D)** Representative primer extension gels to monitor the presence of
 908 m2,2G in tRNA-Met-CAU and mt-tRNA-Ile-GAU from 293T cell lines transfected with the
 909 indicated constructs. m3C₂₀, 3-methylcytosine; m2,2G₂₆, dimethylguanosine; m1G₉, 1-
 910 methylguanosine; >, labeled oligonucleotide used for primer extension; *, background signal. (E,
 911 F) Quantification of m2,2G formation by primer extension for the indicated tRNAs. Primer
 912 extensions were performed three times and error bars represent the standard error of the mean.
 913 Statistical analysis was performed using one-way ANOVA. *P ≤ 0.05; **P ≤ 0.01; ***P ≤
 914 0.001; ****P < 0.0001; ns, non-significant, P > 0.05.



915


916 **Figure 7. TRMT1-ID variants perturb the binding of TRMT1 to RNA.** (A, B) Immunoblot
 917 of whole-cell extracts prepared from 293T human embryonic kidney cells transfected with each
 918 of the indicated FLAG-tagged constructs. Molecular weight in kilodalton is denoted on the right.
 919 (C, D) Nucleic acid stain of RNAs extracted from the indicated input or purified samples after
 920 denaturing polyacrylamide gel electrophoresis. The migration pattern of tRNAs, 5.8S, and 5S
 921 ribosomal RNA is denoted.



922

923 **Figure 8. Location of missense variants in the predicted structure of human TRMT1.** The
924 methyltransferase domain along with the unstructured N-terminus (gray) are shown while the C-
925 terminal zinc finger motif has been omitted. The human TRMT1 model was aligned with
926 *Pyrococcus horikoshii* Trm1 bound to *S*-adenosyl-methionine (PDB: 2EJT) and domains are
927 colored according to (20). The N-terminal Adenosyl-methionine-dependent methyltransferase
928 domain is depicted in blue and C-terminal domain in yellow. Dashed circle represents the
929 putative catalytic active site for binding and methylation of the G26 nucleotide in substrate
930 tRNAs. *S*-adenosyl-methionine is denoted in green. The locations of TRMT1 variants are noted
931 in red.

932



933

934 **Figure 9. Depletion of Trmt1 in zebrafish induces developmental delay and behavioral**
 935 **abnormalities.** (A) RT-qPCR was performed using two sets of primer pairs to examine the
 936 expression levels of *trmt1* mRNA in Cas9 control and *trmt1* F0 knockout animals at 4 dpf.
 937 Experiments were performed with biological and technical triplicates. Expression levels were
 938 normalized to the *18S* housekeeping gene and compared to the Cas9 animals. Error bar =
 939 mean \pm SD. (B, C) LC-MS analysis of m2,2G or m1A in whole larvae or head-only samples. (D)
 940 Representative images for Cas9-injected control (Cas9) and *trmt1* F0 knockouts (F0) at 3 dpf.
 941 (E-G) Quantifications of head, eye, and body sizes for Cas9 and *trmt1* F0 animals. n = 40
 942 embryos each. The values are presented as a percentage of the mean value of Cas9 controls.
 943 Error bars = mean \pm SD. Each dot represents one larva. (H) Locomotor activity analysis, 96-well

944 plates containing 96 larvae at 5 dpf were placed in a recording chamber. Larvae were habituated
945 in the light for 30 minutes, followed by two 30-minute cycles of alternating dark and light cycles.
946 Each point represents the average distance traveled by the animals, with $n = 96$ larvae each. Error
947 bars indicate mean \pm SEM. Black arrows indicate the first minute of light cycles. Black bars at
948 the bottom indicate the first 10 minutes and green bars indicate the last 20 minutes of dark
949 cycles. **(I)** Total distance traveled of each larva in the dark cycles. **(J)** Total distance traveled of
950 each larva in the light cycles. **(K)** Total distance traveled of each larva in the last 20 minutes of
951 dark cycles. **(L)** Average distance traveled calculated for each larva in the first minute of dark
952 cycles. Error bars indicate mean \pm SD. Each dot represents one larva. Mean value of each
953 quantification was presented at the bottom of bar. For (B-D, F-I), statistical significance was
954 calculated by unpaired t test with Welch's correction: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ and
955 $****p < 0.0001$.

References

- 956
957
- 958 1. D. K. Daily, H. H. Arding, G. E. Holmes, Identification and evaluation of mental
959 retardation. *Am Fam Physician* **61**, 1059-1067, 1070 (2000).
 - 960 2. H. M. Knight, M. Demirbugen Oz, A. PerezGrovas-Saltijeral, Dysregulation of RNA
961 modification systems in clinical populations with neurocognitive disorders. *Neural Regen*
962 *Res* **19**, 1256-1261 (2024).
 - 963 3. R. W. Burgess, E. Storkebaum, tRNA Dysregulation in Neurodevelopmental and
964 Neurodegenerative Diseases. *Annu Rev Cell Dev Biol* **39**, 223-252 (2023).
 - 965 4. J. Ramos, D. Fu, The emerging impact of tRNA modifications in the brain and nervous
966 system. *Biochim Biophys Acta Gene Regul Mech* **1862**, 412-428 (2019).
 - 967 5. J. Liu, K. B. Straby, The human tRNA(m²)(2)G(26))dimethyltransferase: functional
968 expression and characterization of a cloned hTRM1 gene. *Nucleic Acids Res* **28**, 3445-3451
969 (2000).
 - 970 6. J. M. Dewe, B. L. Fuller, J. M. Lentini, S. M. Kellner, D. Fu, TRMT1-Catalyzed tRNA
971 Modifications Are Required for Redox Homeostasis To Ensure Proper Cellular Proliferation
972 and Oxidative Stress Survival. *Mol Cell Biol* **37** (2017).
 - 973 7. N. Jonkhout *et al.*, Subcellular relocalization and nuclear redistribution of the RNA
974 methyltransferases TRMT1 and TRMT1L upon neuronal activation. *RNA Biol* **18**, 1905-
975 1919 (2021).
 - 976 8. S. Steinberg, R. Cedergren, A correlation between N²-dimethylguanosine presence and
977 alternate tRNA conformers. *RNA* **1**, 886-891 (1995).
 - 978 9. R. S. Bavi, S. B. Sambhare, K. D. Sonawane, MD simulation studies to investigate iso-
979 energetic conformational behaviour of modified nucleosides m²G and m² 2G present in
980 tRNA. *Comput Struct Biotechnol J* **5**, e201302015 (2013).
 - 981 10. P. S. Pallan, C. Kreutz, S. Bosio, R. Micura, M. Egli, Effects of N²,N²-dimethylguanosine
982 on RNA structure and stability: crystal structure of an RNA duplex with tandem m² 2G:A
983 pairs. *RNA* **14**, 2125-2135 (2008).
 - 984 11. K. Zhang *et al.*, Proteolytic cleavage and inactivation of the TRMT1 tRNA modification
985 enzyme by SARS-CoV-2 main protease. *Elife* **12** (2024).
 - 986 12. A. D'Oliviera *et al.*, Recognition and Cleavage of Human tRNA Methyltransferase TRMT1
987 by the SARS-CoV-2 Main Protease. *bioRxiv* 10.1101/2023.02.20.529306,
988 2023.2002.2020.529306 (2023).
 - 989 13. K. Blaesius *et al.*, Mutations in the tRNA methyltransferase 1 gene TRMT1 cause congenital
990 microcephaly, isolated inferior vermian hypoplasia and cystic leukomalacia in addition to
991 intellectual disability. *Am J Med Genet A* **176**, 2517-2521 (2018).

- 992 14. B. Davarniya *et al.*, The Role of a Novel TRMT1 Gene Mutation and Rare GRM1 Gene
993 Defect in Intellectual Disability in Two Azeri Families. *PLoS One* **10**, e0129631 (2015).
- 994 15. D. Monies *et al.*, The landscape of genetic diseases in Saudi Arabia based on the first 1000
995 diagnostic panels and exomes. *Hum Genet* **136**, 921-939 (2017).
- 996 16. H. Najmabadi *et al.*, Deep sequencing reveals 50 novel genes for recessive cognitive
997 disorders. *Nature* **478**, 57-63 (2011).
- 998 17. K. Zhang *et al.*, An intellectual disability-associated missense variant in TRMT1 impairs
999 tRNA modification and reconstitution of enzymatic activity. *Hum Mutat* **41**, 600-607 (2020).
- 1000 18. F. J. Martin *et al.*, Ensembl 2023. *Nucleic Acids Res* **51**, D933-D941 (2023).
- 1001 19. M. Varadi *et al.*, AlphaFold Protein Structure Database: massively expanding the structural
1002 coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res* **50**,
1003 D439-D444 (2022).
- 1004 20. Ihsanawati *et al.*, Crystal structure of tRNA N2,N2-guanosine dimethyltransferase Trm1
1005 from *Pyrococcus horikoshii*. *J Mol Biol* **383**, 871-884 (2008).
- 1006 21. L. Mosyak, L. Reshetnikova, Y. Goldgur, M. Delarue, M. G. Safro, Structure of
1007 phenylalanyl-tRNA synthetase from *Thermus thermophilus*. *Nat Struct Biol* **2**, 537-547
1008 (1995).
- 1009 22. R. Kaiyrzhanov *et al.*, Bi-allelic ACBD6 variants lead to a neurodevelopmental syndrome
1010 with progressive and complex movement disorders. *Brain* **147**, 1436-1456 (2024).
- 1011 23. S. J. Lin *et al.*, Evaluating the association of biallelic OGDHL variants with significant
1012 phenotypic heterogeneity. *Genome Med* **15**, 102 (2023).
- 1013 24. A. J. Gonzalez-Mantilla, A. Moreno-De-Luca, D. H. Ledbetter, C. L. Martin, A Cross-
1014 Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders.
1015 *JAMA Psychiatry* **73**, 275-283 (2016).
- 1016 25. N. Sobreira, F. Schiettecatte, D. Valle, A. Hamosh, GeneMatcher: a matching tool for
1017 connecting investigators with an interest in the same gene. *Hum Mutat* **36**, 928-930 (2015).
- 1018 26. R. S. Fisher *et al.*, Instruction manual for the ILAE 2017 operational classification of seizure
1019 types. *Epilepsia* **58**, 531-542 (2017).
- 1020 27. F. Alves, P. Kalinowski, S. Ayton, Accelerated Brain Volume Loss Caused by Anti-beta-
1021 Amyloid Drugs: A Systematic Review and Meta-analysis. *Neurology* **100**, e2114-e2124
1022 (2023).
- 1023 28. C. Garel *et al.*, Biometry of the corpus callosum in children: MR imaging reference data.
1024 *AJNR Am J Neuroradiol* **32**, 1436-1443 (2011).

- 1025 29. M. T. Whitehead *et al.*, Refining the Neuroimaging Definition of the Dandy-Walker
1026 Phenotype. *AJNR Am J Neuroradiol* **43**, 1488-1493 (2022).
- 1027 30. S. Efthymiou *et al.*, Biallelic mutations in neurofascin cause neurodevelopmental
1028 impairment and peripheral demyelination. *Brain* **142**, 2948-2964 (2019).
- 1029 31. S. Richards *et al.*, Standards and guidelines for the interpretation of sequence variants: a
1030 joint consensus recommendation of the American College of Medical Genetics and
1031 Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-424 (2015).
- 1032 32. J. M. de Sainte Agathe *et al.*, SpliceAI-visual: a free online tool to improve SpliceAI
1033 splicing variant interpretation. *Hum Genomics* **17**, 7 (2023).
- 1034 33. S. W. Tompson, T. L. Young, Assaying the Effects of Splice Site Variants by Exon
1035 Trapping in a Mammalian Cell Line. *Bio Protoc* **7** (2017).
- 1036 34. A. Rad *et al.*, Aberrant COL11A1 splicing causes prelingual autosomal dominant
1037 nonsyndromic hearing loss in the DFNA37 locus. *Hum Mutat* **42**, 25-30 (2021).
- 1038 35. J. Ramos *et al.*, Identification and rescue of a tRNA wobble inosine deficiency causing
1039 intellectual disability disorder. *RNA* **26**, 1654-1666 (2020).
- 1040 36. J. M. Lentini, H. S. Alsaif, E. Faqeih, F. S. Alkuraya, D. Fu, DALRD3 encodes a protein
1041 mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine
1042 modification. *Nat Commun* **11**, 2510 (2020).
- 1043 37. R. E. Kingston, C. A. Chen, J. K. Rose, Calcium phosphate transfection. *Curr Protoc Mol*
1044 *Biol* **Chapter 9**, Unit 9 1 (2003).
- 1045